Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 2/20 | 0.48 |
| ▸ | CD44 | P16070 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5849939 | 0.98 | RYR2 (0.96) | RYR2KCNH2PNMTCD44MAOB | |
| SCHEMBL4503710 | 0.88 | RYR2 (0.79) | RYR2KCNH2PNMTCD44MAOB | |
| SCHEMBL7200641 | 0.80 | RYR2 (0.65) | RYR2KCNH2MEN1ALDH1A1GAA | |
| SCHEMBL1319961 | 0.78 | RYR2 (0.64) | RYR2KCNH2PNMTCD44MAOB | |
| SCHEMBL4502096 | 0.78 | RYR2 (0.64) | RYR2KCNH2PNMTCD44MAOB | |
| SCHEMBL30509704 | 0.78 | RYR2 (0.64) | RYR2KCNH2PNMTCD44MAOB | |
| SCHEMBL14692217 | 0.77 | RYR2 (0.58) | RYR2KCNH2PNMTCD44MAOB | |
| Piperazine SCHEMBL28173098 | 0.75 | RYR2 (0.60) | RYR2KCNH2PNMTCD44MAOB | |
| SCHEMBL2062318 | 0.73 | RYR2 (0.59) | RYR2KCNH2PNMTCD44MAOB | |
| SCHEMBL14692082 | 0.73 | RYR2 (0.58) | RYR2KCNH2PNMTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116422109-A | Self-extraction layered carbon dioxide trapping system and method | 嘉兴市碳捕手科技有限责任公司 | 2023-07-14 | — | — | CN | claimed |
| US-20140121368-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2014-05-01 | — | — | US | claimed |
| US-8618282-B2 | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes | LES LABORATOIRES SERVIER (FR) | 2013-12-31 | — | — | US | claimed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | claimed |
| EP-2250159-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | Armgo Pharma, Inc. (US) | 2010-11-17 | — | — | EP | claimed |
| US-20100152440-A1 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) | MARKS ANDREW ROBERT | 2010-06-17 | — | — | US | claimed |
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | claimed |
| EP-2127654-A1 | Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases | The Trustees of Columbia University in the City of New York (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2009111463-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | claimed |
| EP-1861385-A1 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | The Trustees of Columbia University in the City of New York (US) | 2007-12-05 | — | — | EP | claimed |
| WO-2006101496-A1 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-09-28 | — | — | WO | claimed |
| US-20050187386-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2005-08-25 | — | — | US | claimed |
| JP-59104371-A | — | — | None | — | — | JP | disclosed |
| JP-10045706-A | — | — | None | — | — | JP | disclosed |
| JP-63162681-A | — | — | None | — | — | JP | disclosed |
| US-4238607-A | ANTIBIOTICS, SEDATIVES, HYPOTENSIVE AGENTS, AND ANTIDEPRESSANTS | ENDO LABORATORIES INC. (US) | 1980-12-09 | — | — | US | disclosed |
| US-4183936-A | SEDATIVES, ANTIDEPRESSANTS, HYPOTENSIVE AGENTS, BACTERICIDES | ENDO LABORATORIES, INC. (US) | 1980-01-15 | — | — | US | disclosed |
| US-4115577-A | SEDATIVES, ANTIDEPRESSANT ANTIHYPERTENSIVE, ANTIBACTERIAL | ENDO LABORATORIES, INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4013652-A | SEDATIVES | ENDO LABORATORIES, INC. (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121368-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, GABRA4 | RYR2 564/4885KCNH2 108/4885PNMT 71/4885 |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, KCNJ2 | RYR2 547/4885KCNH2 103/4885PNMT 74/4885 |
| US-20050187386-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | RYR2, RYR1, ATP2A3 | RYR2 1/4885KCNH2 190/4885PNMT 4072/4885 |
| US-20100152440-A1 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) | RYR2, RYR1, FABP3 | RYR2 1/4885KCNH2 227/4885PNMT 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.